Should I Buy ADPT? ADPT 2026 Analysis

Should You Buy Adaptive Biotechnologies Corp (ADPT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

18.370

1 Day change

-0.70%

52 Week Range

20.760

Analysis Updated At

2026/01/28

Buy now (good buy right now for a beginner long-term investor). The trend is bullish (strong moving-average stack and positive MACD), hedge funds are adding, and Wall Street price targets have been moving up. While the stock is a bit extended short-term (RSI ~70 and sitting near resistance around ~$19.18–$19.86) and earnings on 2026-02-05 can create a sharp move, the overall setup still favors initiating a position immediately rather than waiting.

Technical Analysis

Pre-market ~$19.24 (+0.05%). Trend is bullish: SMA_5 > SMA_20 > SMA_200 confirms an uptrend. MACD histogram is positive (0.212) and expanding, supporting continued upside momentum. RSI_6 ~70.4 suggests the stock is getting stretched/near overbought short-term, which can mean choppier price action. Key levels: Pivot ~18.08 (important support); Resistance R1 ~19.18 (price is slightly above this), then R2 ~19.86. If momentum holds above ~19.18, next technical target is the ~19.86 area; a pullback that holds above ~18.08 would still keep the uptrend intact.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options positioning leans bullish: very low open interest put/call (0.22) indicates calls dominate positioning. Volume put/call (0.75) is not extremely bullish but still suggests more call interest than put interest. Volatility: IV percentile ~4 (very low) and IV rank ~12.7 implies options are relatively cheap vs. the stock’s own history; sentiment looks calm/not panicked. Overall options data supports a constructive (bullish-to-neutral) sentiment backdrop.

Technical Summary

Sell

Buy

Positive Catalysts

1) Strong technical uptrend with momentum (bullish MA stack + expanding positive MACD). 2) Hedge funds are buying (reported +176.86% increase in buying amount over last quarter). 3) Analyst sentiment improving with multiple recent price target raises. 4) Earnings event upcoming (QDEC 2025 earnings on 2026-02-05 after hours) could act as a catalyst if results/outlook beat expectations. 5) Pattern-based projection provided: positive bias over 1 week/month (+3.72% next week, +6.21% next month probabilities cited).

Neutral/Negative Catalysts

1) Short-term extension risk: RSI ~70 and price pressing resistance (~19.18–19.86) can lead to near-term pullbacks. 2) Earnings on 2026-02-05 can cut both ways; a miss or weak guide could reverse momentum quickly. 3) Profitability quality is mixed: latest reported YoY net income and EPS fell sharply (suggests non-linear earnings / potential one-time effects or expense ramps). 4) No supportive near-term news flow in the last week (no fresh narrative catalyst right now).

Financial Performance

Latest reported quarter: 2025/Q3. Revenue grew to ~$93.97M (+102.38% YoY), showing strong top-line acceleration. Gross margin improved to ~80.22% (+26.95% YoY), a meaningful quality-of-revenue positive. However, net income dropped to ~$9.55M (-129.77% YoY) and EPS to $0.06 (-127.27% YoY), indicating earnings are volatile and/or costs/investment are rising versus the prior-year period. Net: growth and margins look strong, but bottom-line consistency is still a concern.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend is improving: multiple firms raised targets after Q3 and into early 2026. Key updates: Guggenheim (2026-01-26) raised PT to $21 (Buy); TD Cowen (2026-01-07) raised PT to $20 (Buy); JPMorgan (2025-11-06) raised PT to $20 (Overweight); Morgan Stanley (2025-11-11) raised PT to $16 but kept Equal Weight. Wall Street pros view: accelerating revenue + improved margins + improving outlook reflected in higher targets. Cons view: at least one major firm remains neutral (Equal Weight), reflecting uncertainty around durability of profitability/cash needs. Influential/politician activity: no recent Congress trading data available; insiders reported as neutral (no significant recent trend). Intellectia Proprietary Trading Signals: No signal on given stock today.

6 Analyst Rating

Wall Street analysts forecast ADPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADPT is 20.25 USD with a low forecast of 20 USD and a high forecast of 21 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 18.500

Low

Averages

20.25

High

Current: 18.500

Low

Averages

20.25

High

Guggenheim

NULL -> Buy

maintain

$20 -> $21

AI Analysis

2026-01-26

New

Reason

Guggenheim

Price Target

$20 -> $21

AI Analysis

2026-01-26

New

maintain

NULL -> Buy

Reason

Guggenheim raised the firm's price target on Adaptive Biotechnologies to $21 from $20 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.

TD Cowen

Buy

maintain

$19 -> $20

2026-01-07

Reason

TD Cowen

Price Target

$19 -> $20

2026-01-07

maintain

Buy

Reason

TD Cowen raised the firm's price target on Adaptive Biotechnologies to $20 from $19 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ADPT

Unlock Now

ADPT Should I Buy

ADPT Should I Buy

Should You Buy Adaptive Biotechnologies Corp (ADPT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch